Selected research
Industry Research
Human Thrombin Industry Research Report 2026
Market perspective
The global Human Thrombin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human Thrombin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human Thrombin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human Thrombin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human Thrombin include RAAS, Hualan Bio, Baxter, Octapharma, Kedrion, Grifols and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human Thrombin market in terms of revenue (US$ million) and, where applicable, sales volume (K Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Thrombin Market by Company
RAAS
Hualan Bio
Baxter
Octapharma
Kedrion
Grifols
CSL
Human Thrombin Segment by Type
500IU
1000IU
2500IU
Human Thrombin Segment by Application
Hospital
Clinic
Other
Human Thrombin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Thrombin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Thrombin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Thrombin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Thrombin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Thrombin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Thrombin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 500IU
- 1000IU
- 2500IU
Applications
- Hospital
- Clinic
- Other
Companies covered
- RAAS
- Hualan Bio
- Baxter
- Octapharma
- Kedrion
- Grifols
- CSL
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human Thrombin Market Size (2021-2032)
- 2.2.2 Global Human Thrombin Sales (2021-2032)
- 2.2.3 Global Human Thrombin Market Average Price (2021-2032)
- 2.3 Human Thrombin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 500IU
- 2.3.3 1000IU
- 2.3.4 2500IU
- 2.4 Human Thrombin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human Thrombin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human Thrombin Sales (K Tons) of Manufacturers (2021-2026)
- 3.3 Global Human Thrombin Revenue of Manufacturers (2021-2026)
- 3.4 Global Human Thrombin Average Price by Manufacturers (2021-2026)
- 3.5 Global Human Thrombin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human Thrombin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human Thrombin, Product Type & Application
- 3.8 Global Manufacturers of Human Thrombin, Established Date
- 3.9 Global Human Thrombin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 RAAS
- 4.1.1 RAAS Company Information
- 4.1.2 RAAS Business Overview
- 4.1.3 RAAS Human Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 RAAS Human Thrombin Product Portfolio
- 4.1.5 RAAS Recent Developments
- 4.2 Hualan Bio
- 4.2.1 Hualan Bio Company Information
- 4.2.2 Hualan Bio Business Overview
- 4.2.3 Hualan Bio Human Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Hualan Bio Human Thrombin Product Portfolio
- 4.2.5 Hualan Bio Recent Developments
- 4.3 Baxter
- 4.3.1 Baxter Company Information
- 4.3.2 Baxter Business Overview
- 4.3.3 Baxter Human Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Baxter Human Thrombin Product Portfolio
- 4.3.5 Baxter Recent Developments
- 4.4 Octapharma
- 4.4.1 Octapharma Company Information
- 4.4.2 Octapharma Business Overview
- 4.4.3 Octapharma Human Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Octapharma Human Thrombin Product Portfolio
- 4.4.5 Octapharma Recent Developments
- 4.5 Kedrion
- 4.5.1 Kedrion Company Information
- 4.5.2 Kedrion Business Overview
- 4.5.3 Kedrion Human Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kedrion Human Thrombin Product Portfolio
- 4.5.5 Kedrion Recent Developments
- 4.6 Grifols
- 4.6.1 Grifols Company Information
- 4.6.2 Grifols Business Overview
- 4.6.3 Grifols Human Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Grifols Human Thrombin Product Portfolio
- 4.6.5 Grifols Recent Developments
- 4.7 CSL
- 4.7.1 CSL Company Information
- 4.7.2 CSL Business Overview
- 4.7.3 CSL Human Thrombin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 CSL Human Thrombin Product Portfolio
- 4.7.5 CSL Recent Developments
5 Global Human Thrombin Market Scenario by Region
- 5.1 Global Human Thrombin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human Thrombin Sales by Region: 2021-2032
- 5.2.1 Global Human Thrombin Sales by Region: 2021-2026
- 5.2.2 Global Human Thrombin Sales by Region: 2027-2032
- 5.3 Global Human Thrombin Revenue by Region: 2021-2032
- 5.3.1 Global Human Thrombin Revenue by Region: 2021-2026
- 5.3.2 Global Human Thrombin Revenue by Region: 2027-2032
- 5.4 North America Human Thrombin Market Facts & Figures by Country
- 5.4.1 North America Human Thrombin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human Thrombin Sales by Country (2021-2032)
- 5.4.3 North America Human Thrombin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Human Thrombin Market Facts & Figures by Country
- 5.5.1 Europe Human Thrombin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human Thrombin Sales by Country (2021-2032)
- 5.5.3 Europe Human Thrombin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Human Thrombin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human Thrombin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human Thrombin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human Thrombin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human Thrombin Market Facts & Figures by Country
- 5.7.1 South America Human Thrombin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human Thrombin Sales by Country (2021-2032)
- 5.7.3 South America Human Thrombin Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Human Thrombin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human Thrombin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human Thrombin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human Thrombin Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Human Thrombin Sales by Type (2021-2032)
- 6.1.1 Global Human Thrombin Sales by Type (2021-2032) & (K Tons)
- 6.1.2 Global Human Thrombin Sales Market Share by Type (2021-2032)
- 6.2 Global Human Thrombin Revenue by Type (2021-2032)
- 6.2.1 Global Human Thrombin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human Thrombin Revenue Market Share by Type (2021-2032)
- 6.3 Global Human Thrombin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human Thrombin Sales by Application (2021-2032)
- 7.1.1 Global Human Thrombin Sales by Application (2021-2032) & (K Tons)
- 7.1.2 Global Human Thrombin Sales Market Share by Application (2021-2032)
- 7.2 Global Human Thrombin Revenue by Application (2021-2032)
- 7.2.1 Global Human Thrombin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human Thrombin Revenue Market Share by Application (2021-2032)
- 7.3 Global Human Thrombin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human Thrombin Value Chain Analysis
- 8.1.1 Human Thrombin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human Thrombin Production Mode & Process
- 8.2 Human Thrombin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human Thrombin Distributors
- 8.2.3 Human Thrombin Customers
9 Global Human Thrombin Analyzing Market Dynamics
- 9.1 Human Thrombin Industry Trends
- 9.2 Human Thrombin Industry Drivers
- 9.3 Human Thrombin Industry Opportunities and Challenges
- 9.4 Human Thrombin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst